Stock 4516 NIPPON SHINYAKU CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

All News Nippon Shinyaku Co., Ltd.

Equities

4516

JP3717600005

Delayed Japan Exchange
Other stock markets
 02:56:18 21/05/2024 BST 		5-day change 1st Jan Change
3,661 JPY -0.87% Intraday chart for Nippon Shinyaku Co., Ltd. -5.64% -26.72%
04-10 Jefferies Adjusts Nippon Shinyaku’s Price Target to 5,100 Yen From 6,900 Yen, Keeps at Buy MT
03-18 Nippon Shinyaku Co., Ltd.(TSE:4516) dropped from S&P Japan Mid Cap 100 CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Nippon Shinyaku : Ending March 2024(FY2023)Presentation Material for IR Meeting (Script)P
PU
Nippon Shinyaku : Ending March 2024(FY2023)Presentation Material for IR MeetingP
PU
Nippon Shinyaku : Outline of Consolidated Financial Results for the Year Ended March 31, 2024
PU
Interim report January-March 2024
AQ
Nippon Shinyaku : Submitted Additional Application of Uptravi® tablets 0.2 mg and 0.4 mg for the Treatment of Pediatric PAH and NDA of Pediatric 0.05 mg formulation to MHLW
PU
Jefferies Adjusts Nippon Shinyaku’s Price Target to 5,100 Yen From 6,900 Yen, Keeps at Buy
MT
MiNA Therapeutics Enters Research Collaboration with Nippon Shinyaku to Develop RNAa Therapeutics Targeting Rare Neurodegenerative Diseases
AQ
Nippon Shinyaku : Announcement of Research Alliance with MiNA Therapeutics in the Field of Central Nervous System
PU
Final dividend
FA
Nippon Shinyaku : UCB Japan Obtained Additional Application of Fintepla® (fenfluramine) for the Treatment of Seizures Associated with Lennox-Gastaut Syndrome in Japan
PU
Nippon Shinyaku : Vyxeos® Combination for I.V. Injection Receives Approval for the Treatment of High-risk AML in Japan
PU
Nippon Shinyaku : Announcement of Alliance Agreement for Pirtobrutinib, a Reversible Non-Covalent BTK Inhibitor in Japan
PU
Nippon Shinyaku Co., Ltd.(TSE:4516) dropped from S&P Japan Mid Cap 100
CI
VILTEPSO® (viltolarsen) injection: Phase II trial (Galactic53 trial) Data presented at the 2024 Muscular Dystrophy Association Clinical & Scientific Conference
PU
Year-end report 2023
AQ
Vicore Pharma Signs Licensing Deal for Idiopathic Pulmonary Fibrosis Drug Candidate
MT
Vicore and Nippon Shinyaku Enter into an Exclusive License Agreement to Develop and Commercialize C21 in Japan
AQ
Nippon Shinyaku : The European Commission Grants Orphan Drug Designation to NS-089/NCNP-02 for the Treatment of Duchenne Muscular Dystrophy
PU
Nippon Shinyaku : Ending March 2024(FY2023)Presentation Material for IR Meeting (2Q FY2023)(Script+Q&A(Summary))P
PU
Capricor Therapeutics Announces $23 Million Registered Direct Offering
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 4516 Stock
  4. News Nippon Shinyaku Co., Ltd.